Immuron Ltd
NASDAQ:IMRN

Watchlist Manager
Immuron Ltd Logo
Immuron Ltd
NASDAQ:IMRN
Watchlist
Price: 0.795 USD 4.26%
Market Cap: 4.8m USD

Operating Margin
Immuron Ltd

-73.5%
Current
-178%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-73.5%
=
Operating Profit
-5.4m
/
Revenue
7.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Immuron Ltd
ASX:IMC
9.7m AUD
-74%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
388.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
172.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
145.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.2B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80B USD
28%
AU
CSL Ltd
ASX:CSL
83.5B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.4B USD
8%
NL
argenx SE
XBRU:ARGX
44.1B EUR
22%
No Stocks Found

Immuron Ltd
Glance View

Market Cap
4.8m USD
Industry
Biotechnology

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.

IMRN Intrinsic Value
2.643 USD
Undervaluation 70%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-73.5%
=
Operating Profit
-5.4m
/
Revenue
7.3m
What is the Operating Margin of Immuron Ltd?

Based on Immuron Ltd's most recent financial statements, the company has Operating Margin of -73.5%.

Back to Top